Literature DB >> 32509189

ASPM is a predictor of overall survival and has therapeutic potential in endometrial cancer.

Jing-Wei Zhou1, Hui Wang1, Wei Sun1, Nan-Nan Han1, Liang Chen1.   

Abstract

BACKGROUND: Endometrial carcinoma (EC) is one of the most common cancers in women, and its pathogenesis is complex. Abnormal spindle microtubule assembly (ASPM) is highly expressed in a variety of cancers and is related to poor clinical prognosis and recurrence. However, the role of ASPM in EC is still unclear. Our study was conducted to investigate the association of ASPM with tumour progression and prognosis in EC.
METHODS: The expression level of ASPM in EC patients was analysed by using the TCGA database and by using immunohistochemistry (IHC) to analyse EC patient samples. The relationship between ASPM expression and clinicopathological variables was analysed by the chi-square test. Survival curves were analysed by Kaplan-Meier survival analysis and log-rank test. Univariate and multivariate Cox regression analyses were performed to measure the prognosis of EC. The effects of ASPM on the proliferation, invasion and metastasis of EC cells (HEC-1A and Ishikawa) were analysed by MTT and Transwell assays. The effect of ASPM on the Wnt/β-catenin signalling pathway was detected by Western blotting.
RESULTS: ASPM was highly overexpressed in EC. Overexpression of ASPM was related to significantly worse overall survival (P<0.05) in EC patients. Univariate and multivariate Cox regression analyses suggested that upregulation of ASPM was related to poor prognosis in EC. Knockdown of ASPM inhibited the proliferation, migration and invasion of EC cells. ASPM knockdown suppressed the Wnt/β-catenin signalling pathway, while β-catenin overexpression reversed the effect of shASPM on cell activity.
CONCLUSIONS: ASPM acts as an independent predictor of clinical prognosis and serves as a potential target gene for EC therapy. AJTR
Copyright © 2020.

Entities:  

Keywords:  ASPM; Wnt/β-catenin; endometrial carcinoma; prognosis

Year:  2020        PMID: 32509189

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  7 in total

1.  Abnormal spindle-like microcephaly-associated protein promotes proliferation by regulating cell cycle in epithelial ovarian cancer.

Authors:  Yiguo Wu; Yujuan You; Ling Chen; Yue Liu; Yujuan Liu; Weiming Lou; Fen Fu
Journal:  Gland Surg       Date:  2022-04

2.  Metabolite Effect on Angiogenesis: Insights from Transcriptome Analysis.

Authors:  P Sunitha; Kesavan R Arya; Achuthsankar S Nair; Oommen V Oommen; Perumana R Sudhakaran
Journal:  Cell Biochem Biophys       Date:  2022-06-14       Impact factor: 2.989

3.  Oncogenic role of abnormal spindle‑like microcephaly‑associated protein in lung adenocarcinoma.

Authors:  Jiang Wang; Jinghui Liang; Haixia Li; Jingyi Han; Jin Jiang; Yongmeng Li; Zitong Feng; Renchang Zhao; Hui Tian
Journal:  Int J Oncol       Date:  2021-03-31       Impact factor: 5.650

4.  Identification of key biomarkers and functional pathways in osteosarcomas with lung metastasis: Evidence from bioinformatics analysis.

Authors:  Denghua Liu; Rui Zhou; Aiguo Zhou
Journal:  Medicine (Baltimore)       Date:  2021-02-12       Impact factor: 1.817

5.  ASPM Is a Prognostic Biomarker and Correlates With Immune Infiltration in Kidney Renal Clear Cell Carcinoma and Liver Hepatocellular Carcinoma.

Authors:  Tingting Deng; Yang Liu; Jialang Zhuang; Yizhe Tang; Qin Huo
Journal:  Front Oncol       Date:  2022-04-20       Impact factor: 5.738

6.  ASPM promotes homologous recombination-mediated DNA repair by safeguarding BRCA1 stability.

Authors:  Shibin Xu; Xingxuan Wu; Peipei Wang; Sheng-Li Cao; Bin Peng; Xingzhi Xu
Journal:  iScience       Date:  2021-05-12

7.  Identification of potential biomarkers associated with immune infiltration in papillary renal cell carcinoma.

Authors:  Ran Deng; Jianpeng Li; Hong Zhao; Zhirui Zou; Jiangwei Man; Jinlong Cao; Li Yang
Journal:  J Clin Lab Anal       Date:  2021-10-04       Impact factor: 2.352

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.